France vs. Andes Hantavirus: The Extraordinary Biosecurity Operation That Stopped a Potential Outbreak from MV Hondius

ABSTRACT

 

The outbreak of Andes hantavirus (ANDV) aboard the cruise ship MV Hondius in May 2026 raised significant global public health concerns due to the virus’s unique pathogenic characteristics compared with other hantaviruses, particularly its demonstrated capacity for human-to-human transmission. Following the vessel’s arrival in Tenerife, Spain, the French government rapidly repatriated five French nationals who had been exposed during the voyage. This article examines the emergency response measures implemented by French authorities in managing these imported cases, including medical evacuation procedures, airborne biocontainment systems, high-level clinical isolation, molecular diagnostics conducted by the Institut Pasteur, and contact tracing during an extended incubation period. The analysis demonstrates that a multilayered approach based on biosecurity, biosafety, and field epidemiology principles successfully prevented local transmission within France. Furthermore, this article discusses the genetic characteristics of the Andes virus isolated from the French patient and compares French isolation protocols with those implemented in the United States. This experience provides an important model for responding to emerging zoonotic diseases with human-to-human transmission potential in an era of increasing global mobility.

Keywords: Andes hantavirus, MV Hondius, biosecurity, clinical isolation, Institut Pasteur, medical repatriation, Hantavirus Pulmonary Syndrome (HPS).

 

1. INTRODUCTION

 

On 4 May 2026, the World Health Organization (WHO) issued an international alert regarding an outbreak of severe respiratory illness aboard the cruise ship MV Hondius, which was sailing from Ushuaia, Argentina, to Cape Verde. Virological investigations conducted by international health authorities subsequently identified the causative agent as Andes hantavirus (ANDV), a member of the genus Orthohantavirus endemic to South America (WHO, 2026; ECDC, 2026).

Andes hantavirus possesses epidemiological characteristics that distinguish it from most other hantaviruses. While the majority of hantaviruses are transmitted through aerosols contaminated with rodent excreta, ANDV is the only hantavirus conclusively demonstrated to be capable of human-to-human transmission through prolonged close contact. The virus can cause Hantavirus Pulmonary Syndrome (HPS), a severe disease with reported case-fatality rates ranging from 30% to 60% in severe cases.

During the international evacuation process in Tenerife, five French citizens were repatriated to Paris aboard a dedicated medical flight. One passenger developed symptoms during the journey and was subsequently confirmed positive for ANDV by the Institut Pasteur. This case became a critical test of France’s preparedness for managing high-risk emerging infectious diseases.

The objective of this article is to analyze France’s clinical and epidemiological response to imported ANDV cases, including viral genetic characterization and a comparison of response protocols with those adopted by other countries.

 

2. METHODOLOGY

 

This study employed a descriptive case-study approach based on document analysis. Data were obtained from reports published by the Institut Pasteur, the European Centre for Disease Prevention and Control (ECDC), the European Commission, the World Health Organization, and other official publications released during May 2026.

The analysis focused on:

1. Medical evacuation and repatriation systems.
2. Laboratory diagnostics and viral genetic characterization.
3. Clinical management of confirmed cases.
4. Contact tracing and epidemiological surveillance.
5. Comparative analysis of isolation policies in France and the United States.

 

3. RESULTS AND DISCUSSION

 

3.1 Medical Evacuation and Airborne Biocontainment Protocols

Following disembarkation in Tenerife on 10 May 2026, all passengers considered to be at high risk were evacuated using non-commercial flights in accordance with ECDC recommendations. France repatriated its five citizens aboard a private aircraft specially configured for the transport of patients with high-consequence infectious diseases.

The principal measures implemented included:

• Separation of high-risk individuals from the general population.
• Use of personal protective equipment (PPE) by medical personnel.
• Strict control of cabin airflow.
• Activation of compartmentalized quarantine procedures when a passenger developed symptoms during the flight.

These measures were consistent with international guidelines for the transportation of patients with dangerous infectious diseases.

 

3.2 Diagnostic Procedures and Genetic Characterization of Andes Hantavirus

The French case was diagnosed by the Emergency Biological Intervention Unit (CIBU) of the Institut Pasteur in collaboration with the French National Reference Center for Hantaviruses. Molecular testing using reverse transcription polymerase chain reaction (RT-PCR) confirmed infection with Andes hantavirus.

Genetic Characteristics of the Virus

Whole-genome sequencing results announced by the Institut Pasteur on 15 May 2026 revealed that:

1. The viral isolate obtained from the French patient was genetically identical to isolates identified in other confirmed MV Hondius cases.
2. The viral sequence exhibited more than 95% nucleotide similarity with Andes virus strains circulating in southern South America.
3. No novel mutations associated with increased virulence or enhanced human-to-human transmissibility were detected.
4. There was no evidence of the emergence of a biologically distinct variant compared with previously characterized Andes virus strains.

These findings were important in reducing public concern regarding the possible emergence of a more transmissible strain.

 

Genomic Structure of Andes Hantavirus (ANDV)

Like other members of the genus Orthohantavirus, Andes hantavirus (ANDV) possesses a tripartite genome composed of three segments of negative-sense single-stranded RNA (ssRNA): the Small (S), Medium (M), and Large (L) segments. The S segment encodes the nucleocapsid (N) protein, a multifunctional structural protein that encapsidates viral RNA, protects the genome from degradation, and participates in the formation of ribonucleoprotein complexes required for viral replication and transcription. The M segment encodes a glycoprotein precursor that is subsequently cleaved into two envelope glycoproteins, Gn and Gc, which are embedded in the viral lipid envelope and mediate attachment to and entry into susceptible host cells. The L segment encodes the viral RNA-dependent RNA polymerase (RdRp), an essential enzyme responsible for transcription of viral messenger RNA and replication of the viral genome. Together, these three genomic segments coordinate the complete viral replication cycle and determine the pathogenic potential of the virus.

The molecular functions of the proteins encoded by these genomic segments are closely associated with the pathogenesis of Hantavirus Pulmonary Syndrome (HPS). The Gn and Gc glycoproteins interact primarily with β3 integrin receptors expressed on pulmonary microvascular endothelial cells, facilitating viral attachment, membrane fusion, and cellular entry. Infection of endothelial cells results in increased vascular permeability, a hallmark of severe HPS, leading to pulmonary edema, respiratory failure, and cardiopulmonary compromise. Meanwhile, the nucleocapsid protein not only supports viral replication by binding genomic RNA but also modulates host innate immune responses through interactions with cellular signaling pathways, thereby contributing to viral persistence and immune evasion. The RNA-dependent RNA polymerase encoded by the L segment drives genome replication and transcription within the cytoplasm of infected cells. Advances in genomic sequencing have demonstrated that variations within the S, M, and L segments may influence viral fitness, virulence, host adaptation, and transmission dynamics. Consequently, whole-genome characterization of ANDV isolates has become an important tool for molecular epidemiology, outbreak investigation, phylogenetic analysis, and the identification of genetic markers associated with enhanced pathogenicity or human-to-human transmission.

 

3.3 Clinical Management of the French Patient

The patient who developed symptoms during the repatriation flight was immediately transferred to the high-consequence infectious disease unit at Bichat-Claude Bernard Hospital in Paris.

Table 1. Clinical Management Protocol

Phase	Intervention
Initial isolation	High-level negative-pressure isolation room
Monitoring	Continuous hemodynamic and respiratory monitoring
Intensive care	Mechanical ventilation in cases progressing to HPS
Supportive therapy	Intravenous fluids, vasopressors, and correction of organ dysfunction
Nosocomial prevention	Full PPE and restricted access to isolation facilities

As no specific antiviral therapy has yet been approved for ANDV infection, treatment focused primarily on intensive supportive care.

 

3.4 Contact Tracing and Epidemiological Surveillance

Given the potential for human-to-human transmission, French health authorities conducted an intensive epidemiological investigation.

Identification of Close Contacts

A total of 22 close contacts were identified and enrolled in an active health-monitoring program.

Quarantine and Monitoring

In accordance with ECDC recommendations, all contacts underwent:

• Home or designated-facility quarantine.
• Daily temperature monitoring.
• Surveillance for respiratory symptoms.
• Periodic laboratory testing.

Forty-Two-Day Surveillance Period

Because the incubation period of ANDV may extend up to six weeks, French authorities established a 42-day observation period. This policy was more conservative than surveillance periods commonly applied to many other viral respiratory diseases.

By 14 May 2026, all monitored contacts had tested negative for infection.

 

3.5 Public Risk Communication

The French Ministry of Health and the Institut Pasteur implemented a transparent risk communication strategy emphasizing that:

• The risk to the general public remained extremely low.
• No novel viral mutations had been identified.
• Transmission requires prolonged close contact.
• The situation was not comparable to the COVID-19 pandemic.

This communication strategy played a critical role in preventing public panic and maintaining confidence in public health authorities.

 

3.6 Comparison of French and United States Isolation Protocols

France

The French response was characterized by:

• Repatriation using dedicated medical flights.
• Isolation within designated national referral hospitals.
• Utilization of negative-pressure isolation rooms.
• Forty-two-day contact monitoring.
• Centralized diagnostic testing through the Institut Pasteur.

United States

The United States also repatriated passengers from the MV Hondius and implemented interstate contact-tracing measures. Epidemiological investigations were conducted across at least seven states involving returning passengers. The first confirmed U.S. case was reported in the state of Nebraska.

Key Differences Between the Two Approaches

Aspect	France	United States
Diagnostic system	Centralized through Institut Pasteur	Decentralized through federal and state laboratory networks
Isolation system	National referral hospitals	State-dependent healthcare facilities
Contact quarantine	Nationally coordinated 42-day monitoring	Coordinated by individual state authorities
Public communication	Centralized national messaging	Multi-level communication involving CDC, state authorities, and hospitals

The French model demonstrated a higher degree of national coordination, whereas the U.S. system relied on a more decentralized public health structure.

 

4. CONCLUSION

 

The imported Andes hantavirus cases associated with the MV Hondius cluster in May 2026 highlight the importance of preparedness for emerging zoonotic diseases capable of human-to-human transmission. France implemented a rapid and integrated response involving biocontainment medical repatriation, high-level clinical isolation, genomic diagnostics conducted by the Institut Pasteur, and a 42-day contact-tracing and surveillance program.

Genomic analysis demonstrated that the virus isolated from the French patient was highly similar to Andes virus strains circulating in South America and exhibited no mutations associated with increased epidemiological risk. The combination of biosafety measures, biosecurity protocols, epidemiological surveillance, and effective risk communication successfully prevented secondary local transmission within France.

This experience provides a valuable model for other countries confronting cross-border infectious disease threats in an era characterized by globalization and extensive international travel.

 

REFERENCES

 

European Centre for Disease Prevention and Control (ECDC). 2026. Andes Hantavirus Outbreak in Cruise Ship, May 2026. Stockholm: ECDC.

 

European Centre for Disease Prevention and Control (ECDC). 2026. Andes Hantavirus Outbreak: ECDC Continues Working on the Frontline to Support EU Member States. Stockholm: ECDC.

 

European Commission. 2026. Hantavirus Outbreak 2026. Brussels: European Commission.

 

Institut Pasteur. 2026. Andes Virus on the MV Hondius Cruise Ship: What We Know About This Rare and Potentially Fatal Hantavirus. Paris: Institut Pasteur.

 

Institut Pasteur. 2026.L'Institut Pasteur Confirme par Séquençage Complet l'Origine Latino-Américaine de l'Hantavirus Andes Détecté à Bord du MV Hondius. Paris: Institut Pasteur.

 

Jonsson CB, Figueiredo LTM, Vapalahti O. 2010. A Global Perspective on Hantavirus Ecology, Epidemiology, and Disease. Clinical Microbiology Reviews, 23(2): 412–441.

 

MacNeil A, Nichol ST, Spiropoulou CF. 2011. Hantavirus Pulmonary Syndrome. Virus Research, 162(1–2): 138–147.

 

Martinez-Valdebenito C, Calvo M, Vial C, et al. 2014. Person-to-Person Household and Nosocomial Transmission of Andes Hantavirus, Southern Chile, 2011. Emerging Infectious Diseases, 20(10): 1629–1636.

 

Vial PA, Valdivieso F, Ferres M, et al. 2006. High-Dose Intravenous Methylprednisolone for Human Hantavirus Cardiopulmonary Syndrome in Chile. Clinical Infectious Diseases, 42(4): e1–e8.

 

World Health Organization (WHO). 2026. Hantavirus Outbreak Toolbox and International Situation Reports Related to MV Hondius. Geneva: WHO.

 

#AndesHantavirus

#MVHondius

#BiosecurityStrategy

#PublicHealthResponse

#EmergingInfectiousDiseases